Company Halts Sale of Laproscopic Power Morcellators Used in Fibroid Surgery

Following a FDA advisory earlier in the month of an increased risk of cancer spread, Johnson and Johnson suspended the global sale of a device used in fibroid surgery.

Johnson & Johnson

suspended worldwide sale of its device used in fibroid surgery amid concerns over its potential to spread undetected cancer beyond the uterus.

The company said it is suspending the sale of its power morcellators until their role in fibroid treatment is better understood and redefined by the medical community.

The action follows a Food and Drug Administration advisory on April 17 that discouraged doctors from using laparoscopic power morcellators to remove fibroids because of a risk of worsening an often-hidden cancer. (

"Ethicon morcellation devices have always included cautions in their instructions for use about the potential spread of malignant tissue," J&J wrote in a letter to customers, a copy of which is available with Reuters.

Read the complete story here:

Source: Reuters

Related Videos
View All
Related Content
© 2023 MJH Life Sciences
All rights reserved.